Mednet Logo
Community

Would you consider immunotherapy in high-risk resectable MSI-H colorectal cancer?

Specifically, would you consider either neoadjuvant or adjuvant immunotherapy in this setting, or only after recurrence?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on

Immunotherapy demonstrated great activity in treating metastatic MSI-H colorectal cancer (CheckMate 142 study, KEYNOTE-177 study, etc). There are now several small studies showing the activity of immunotherapy in early stage or locally advanced colorectal cancer.

The NICHE study enrolled 40 patients...

Join for free or sign in to see the full answer